Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044–60.

Article  PubMed  PubMed Central  Google Scholar 

Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847–56.

Article  CAS  PubMed  Google Scholar 

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65.

Article  CAS  PubMed  Google Scholar 

Schoenfeld AJ, Rizvi H, Bandlamudi C, Sauter JL, Travis WD, Rekhtman N, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020;31(5):599–608.

Article  CAS  PubMed  Google Scholar 

Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e93–503.

Article  Google Scholar 

Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Oncotargets Ther. 2018;11:955–65.

Article  Google Scholar 

Iivanainen S, Ahvonen J, Knuuttila A, Tiainen S, Koivunen JP. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open. 2019;4(4):e000531.

Article  PubMed  PubMed Central  Google Scholar 

Petrelli F, Ardito R, Merelli B, Lonati V, Cabiddu M, Seghezzi S, et al. Prognostic and predictive role of elevated lactate dehydrogenase in patients with Melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Melanoma Res. 2019;29(1):1–12.

Article  CAS  PubMed  Google Scholar 

Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting recommendations for Tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst. 2018;110(8):803–11.

Article  PubMed  PubMed Central  Google Scholar 

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, et al. Management of Anaemia and Iron Deficiency in patients with Cancer: ESMO Clinical Practice guidelines. Ann Oncol. 2018;29:iv96–110.

Article  CAS  PubMed  Google Scholar 

Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg M, Martino M, et al. Management of Cancer-Associated Anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice Guideline Update. J Clin Oncol. 2019;37(15):1336–51.

Article  CAS  PubMed  Google Scholar 

Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J. RECIST - learning from the past to build the future. Nat Rev Clin Oncol. 2017;14(3):187–92.

Article  PubMed  Google Scholar 

Delgado A, Guddati AK. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021;11(4):1121–31.

PubMed  PubMed Central  Google Scholar 

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the lung Immune Prognostic Index with Immune checkpoint inhibitor outcomes in patients with Advanced Non-small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351–7.

Article  PubMed  PubMed Central  Google Scholar 

Pan Y, Si H, Deng G, Chen S, Zhang N, Zhou Q, et al. A Composite Biomarker of Derived Neutrophil-Lymphocyte ratio and platelet-lymphocyte ratio correlates with outcomes in Advanced gastric Cancer patients treated with Anti-PD-1 antibodies. Front Oncol. 2022;11:798415.

Article  PubMed  PubMed Central  Google Scholar 

Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in Melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced Melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74.

Article  PubMed  PubMed Central  Google Scholar 

Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic Melanoma patients. Br J Cancer. 2015;112(12):1904–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stukalin I, Navani V, Gupta M, Ruan Y, Boyne DJ, O’Sullivan DE et al. Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2023:oyad073.

Chen X, Li Z, Zhou J, Wei Q, Wang X, Jiang R. Identification of prognostic factors and nomogram model for patients with advanced Lung cancer receiving immune checkpoint inhibitors. PeerJ. 2022;10:e14566.

Article  PubMed  PubMed Central  Google Scholar 

Gao Y, Rosen JM, Zhang XH. The tumor-immune ecosystem in shaping Metastasis. Am J Physiol Cell Physiol. 2023;324(3):C707–17.

Article  CAS  PubMed  Google Scholar 

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zahid KR, Raza U, Tumbath S, Jiang L, Xu W, Huang X. Neutrophils: musketeers against immunotherapy. Front Oncol. 2022;12:975981.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.

Article  PubMed  Google Scholar 

Chen X, Meng F, Jiang R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with metastatic renal cell carcinoma treated with Immune Checkpoint inhibitors: a systematic review and Meta-analysis. Front Oncol. 2021;11:746976.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Meng Y, Sun H, Ye L, Zeng F, Chen X, et al. The Prognostic significance of baseline neutrophil-to-lymphocyte ratio in Melanoma patients receiving immunotherapy. J Immunother. 2022;45(1):43–50.

Article  CAS  PubMed  Google Scholar 

Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, et al. Platelet first responders in wound response, cancer, and Metastasis. Cancer Metastasis Rev. 2017;36(2):199–213.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al Jarroudi O, El Bairi K, Abda N, Zaimi A, Jaouani L, Chibani H, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in Inflammatory Breast cancer. Biomark Med. 2021;15(14):1289–98.

Article  CAS  PubMed  Google Scholar 

Yuan Y, Zhong H, Ye L, Li Q, Fang S, Gu W, et al. Prognostic value of pretreatment platelet counts in Lung cancer: a systematic review and meta-analysis. BMC Pulm Med. 2020;20(1):96.

Article  PubMed  PubMed Central  Google Scholar 

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell Lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–81.

Article  PubMed  Google Scholar 

Hart PC, Rajab IM, Alebraheem M, Potempa LA. C-Reactive protein and Cancer-Diagnostic and Therapeutic insights. Front Immunol. 2020;11:595835.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riedl JM, Barth DA, Brueckl WM, Zeitler G, Foris V, Mollnar S, et al. C-Reactive protein (CRP) levels in Immune checkpoint inhibitor response and progression in Advanced Non-small Cell Lung Cancer: a Bi-center Study. Cancers (Basel). 2020;12(8):2319.

Article  CAS  PubMed  Google Scholar 

Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60(5):1443–50.

CAS  PubMed  Google Scholar 

Kornum JB, Farkas DK, Sværke C, Severinsen MT, Thomsen RW, Sørensen HT. Cancer Risk and Prognosis after a hospital contact for an elevated erythrocyte sedimentation rate. Cancer Epidemiol Biomarkers Prev. 2019;28(1):225–32.

Article  PubMed  Google Scholar